Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief Development Officer

Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief Development Officer

June 28, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 28, 2013-- 

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today that it has appointed biologics industry veteran Karen L. Tubridy, PharmD, as Chief Development Officer. She will be responsible for leading and executing the company's clinical and regulatory development strategy, currently focused on innovative protein therapeutics for ocular diseases. Ms. Tubridy will be a member of Eleven's management team reporting to Abbie Celniker, PhD, Chief Executive Officer, and she will play a key role in advancing the clinical development of the company's lead ocular product candidate, EBI-005, in collaboration with Michael H. Goldstein, MD, Eleven's medical director and the co-director of the Cornea, External Disease and Cataract Service group at Tufts University Medical Center.

"Karen Tubridy is joining Eleven at an exciting time in the company's evolution. EBI-005, the first IL-1 signaling inhibitor designed for topical ocular administration, has just completed a Phase 1b clinical study in patients with dry eye disease and Karen will play a key role in further advancing the clinical development of EBI-005 based on its positive clinical progress to-date," said Abbie Celniker, PhD, Chief Executive Officer of Eleven Biotherapeutics. "We look forward to leveraging Karen's extensive global development experience, including clinical and regulatory strategies specific to biotherapeutic product candidates, as we continue to advance EBI-005 into later stage clinical development."

"Eleven's technology has clearly demonstrated the ability to create novel biotherapeutics with improved characteristics and therapeutic benefits, with EBI-005 as a prime example of the promising therapeutic potential of proteins from Eleven's R&D engine," said Ms. Tubridy. "I am excited to be joining Eleven and look forward to working with the team to advance EBI-005 to its full potential, as well as exploring other promising opportunities."

Ms. Tubridy has more than 20 years of experience directing global clinical programs, developing regulatory and clinical strategies, and leading development programs of novel and first-in-class biotherapeutics. Karen Tubridy most recently served as Senior Vice President, Clinical Development and Medical Affairs at Inspiration Biopharmaceuticals where she successfully led the clinical, medical and regulatory functions of the company's lead product candidates, OBI-1, which was acquired by Baxter in March 2013 for more than $700 million and IB1001 which was acquired by Cangene. Before Inspiration, Ms. Tubridy was Executive Director, Clinical Operations and Regulatory Affairs, Translational Medicine at Alexion Pharmaceuticals and Taligen Therapeutics (which was acquired by Alexion). Prior to Alexion, Karen Tubridy held similar clinical operations and regulatory positions of increasing responsibility at Syntonix Pharmaceuticals (which was acquired by Biogen Idec), AVANT Immunotherapeutics, Wyeth, Genetics Institute and New England Medical Center. Ms. Tubridy received her BSc and PharmD from Massachusetts College of Pharmacy and Allied Health Sciences.

About Eleven Biotherapeutics

Eleven Biotherapeutics creates novel and differentiated biotherapeutics: first-of-a-kind protein-based drugs with significantly improved physical, pharmaceutical, and therapeutic benefits. The company's AMP-Rx(TM) product engine brings capabilities beyond conventional approaches for making protein therapeutics, opening up new territory for the products to have novel structures, enhanced biophysical properties, and more effective targeting in disease pathways. Eleven's success is built on designing proteins 'fit for purpose' that are rationally designed to have ideal therapeutic characteristics and result in best-in-class biotherapeutic products for a wide range of diseases. The Cambridge, Mass.-based company was founded in 2010 by life science investors Flagship Ventures and Third Rock Ventures and world-renowned scientific experts. For more information, please visit www.elevenbio.com.

CONTACT: Eleven Biotherapeutics

Cameron Wheeler, PhD, 617-858-0927

cameron@elevenbio.com

or

Media:

The Yates Network

Gina Nugent, 617-460-3579

gina@theyatesnetwork.com